SAN DIEGO, March 12, 2002 (PRIMEZONE) -- CardioDynamics (Nasdaq:CDIC), the innovator and global leader of Impedance Cardiography (ICG) technology, today announced that a significant ICG study was published in the February 2002 issue of peer-reviewed The Journal of Cardiothoracic and Vascular Anesthesia. The study was designed to evaluate whether measurements of cardiac index (the amount of blood pumped by the heart each minute) using BioZ noninvasive technology was equivalent to the standard invasive Pulmonary Artery Catheter. The researchers chose to study patients immediately following open-heart surgery because these patients are known to show significant hemodynamic (blood-flow) instability in the first 12 to 18 hours after surgery, and represent one of the most frequent uses of the Pulmonary Artery Catheter. The results were dramatic and revealed clinical equivalence between the BioZ and PAC measurements.
Commenting on the study, lead investigator, W. Scott Sageman, M.D., stated: "The interest in, and demand for, an accurate noninvasive method of measuring cardiac output is high. While this study demonstrated exceptional agreement between the thermodilution and BioZ-derived measurements in this patient group, its additional significance is the demonstration of an extraordinary degree of tracking of these measures over time. The potential impact, in terms of reducing morbidity while reducing costs, is substantial given the annual $1 billion burden that currently exists with PAC use in cardiac surgery procedures. This data is very encouraging regarding the role that impedance cardiography technology can play in cardiac monitoring and healthcare."
Michael K. Perry, Chief Executive Officer of CardioDynamics, stated: "We are pleased to see this study published in the peer-reviewed and respected Journal of Cardiothoracic and Vascular Anesthesia. This study is significant because it demonstrates that the information provided by our noninvasive BioZ is clinically equivalent to an invasive, risky and more costly procedure in patients that challenge cardiac monitoring by their blood flow instability after surgery. With each new study, the value of our proprietary ICG technology is further established, and we move closer to becoming a safe, noninvasive and cost-effective standard of care in cardiac monitoring."
About CardioDynamics
CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator and global leader of breakthrough medical technology called Impedance Cardiography (ICG). The Company's primary products, the BioZ(r) Systems, are being used by leading physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Medical Systems Information Technologies, Spacelabs Medical Systems and Vasomedical. The worldwide market potential for BioZ products is estimated to be $5 billion and an additional $800 million in recurring annual revenue for disposables. For additional information or to request an investor package, please refer to the company's Web site at www.cdic.com.
Forward-Looking (Safe Harbor) Statement
Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 2001 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.